Behandlung diffus-großzelliger B-Zell-Lymphome

Zusammenfassung

Diffus-großzellige B-Zell Lymphome (DLBCL) stellen mit ca. 40 % die größte Gruppe aller Lymphome dar. Durch die Entwicklung dosisdichter Chemotherapieregime sowie die Einführung des monoklonalen CD20-Antikörpers Rituximab hat sich die Prognose fast aller Patienten mit diffus-großzelligen B-Zell Lymphomen deutlich verbessert. Klinische Risikofaktoren (Alter, Stadium, LDH, Allgemeinzustand nach ECOG performance status, Ausmaß des extranodalen Befalls), die bei Diagnosestellung evaluiert werden, stellen bislang die wirksamste Möglichkeit einer Risikostratifizierung dar. Eine kombinierte Chemo-Immuntherapie mit R-CHOP ist der Therapiestandard, der anhand vorliegender Risikofaktoren modifiziert wird.

Summary

Diffuse large B-cell lymphoma represent 40 % of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are the most important approaches for risk stratification that allows risk adapted modifications of the standard R-CHOP regimen.

Schlüsselwörter

diffus-großzellige Lymphome - Risikofaktoren - Chemo-Immuntherapie - R-CHOP

Key words

diffuse large cell lymphoma - risk factors - chemoimmunotherapy - R-CHOP

Literatur

• 1 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-42
• 2 Dunleavy K, Pittaluga S, Janik J. et al . Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation.  Blood. 2005;  106 273A
• 3 Fisher R I, Gaynoer E R, Dahlberg S. et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.  N Eng J Med. 1993;  328 1002-6
• 4 Glass B, Kloess M, Reiser M. et al . Dose-escalated CHOP + Etoposide followed by repetitive autologous stem cell transplantation (MegaCHOEP) with or without rituximab for primary treatment of aggressive NHL.  Blood. 2006;  106 1492a
• 5 Gleissner B, Küppers R, Siebert R. et al .Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. Brit J Haemtol in press
• 6 Haioun C, Itti E, Rahmoundi A. et al . [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.  Blood. 2005;  106 (4) 1376-81 , . Epub 2005 Apr 28
• 7 Harris N L, Jaffe E S, Diebold J. et al . The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.  Mod Pathol. 2000;  13 193-207
• 8 Hoelzer D, Hiddemann W, Baumann A. et al .High cure rate of adult Burkitt’s and other high grade NHL by the combination of short intensive chemotherapy cycles with rituximab. Annual Meeting European Organization of Haematology EHA 2007: 0410a
• 9 http://www.krebsregister.saarland.de/publikationen/PDF/Publikation40Jahre.pdf. 
• 10 Hummel M, Bentink S, Berger H. et al . A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling.  New England Journal of Medicine. 2006;  354 2419-2430
• 11 Küppers R. Mechanisms of B-cell pathogenesis.  Nat Rev Cancer. 2005;  5 (4) 251-262
• 12 Miller T P, LeBlanc M, Spier C. et al . CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: Update of the Southwest Oncology Group randomized trial.  Blood. 2001;  98 724a
• 13 Pfreundschuh M, Trümper L, Kloess M. et al . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSNHL.  Blood. 2004;  104 626-33
• 14 Pfreundschuh M, Schubert J, Ziepert M. et al . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).  Lancet Oncol. 2008;  9 105-116
• 15 Pfreundschuh M, Trumper L, Osterborg A. et al . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.  Lancet Oncol. 2006;  7 379-391
• 16 Reyes F, Lepage E, Ganem G. et al . ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.  N Eng J Med. 2005;  352 1197-205
• 17 Schmitz N, Kloess M, Reiser M. et al . Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation.  Cancer. 2006;  106 136-45
• 18 Seam P, Juweid M F, Cheson B D. The role of FDG-PET scans in patients with lymphoma.  Blood. 2007;  110 (10) 3507-16 , . Epub 2007 Aug 2
• 19 Shipp M A. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has „high-risk” disease?.  Blood. 1994;  83 1165-1173
• 20 Tilly H, Lipage E, Coiffier B. et al . Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.  Blood. 2003;  102 4284-4289
• 21 Zinzani P L, Martelli M, Bertini M. et al . Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.  Haemagologica. 2002;  87 1258-64